This document is a publication of a United States Patent Application (US20260083778A1) filed by Boston Medical Center Corporation. The application details methods for generating specific types of T cells (CD4+CD8− single-positive T cells) from progenitor cells using a defined process involving interleukin-7 (IL-7) and an anti-CD3 agent, while excluding a Notch ligand and an anti-CD28 agent. The described cells and methods are intended for therapeutic applications.

As this is a patent application publication, it does not impose direct compliance obligations on regulated entities. However, it signals potential future developments in cell therapy and immunotherapy. Companies involved in biotechnology, pharmaceutical research, and cell-based therapeutics should monitor patent filings in this area for insights into emerging technologies and potential intellectual property landscapes. No immediate actions or deadlines are associated with this publication.